Implantation of a hydrophobic acrylic monofocal intraocular lens in a preloaded injector

Aim. To evaluate clinical and functional results of implantation of a new hydrophobic acrylic monofocal IOL in a preloaded injector. Methods. The prospective study included 60 patients (66 eyes) after Hoya iSert® 250/251 IOL implantation (31 patients, 35 eyes, group 1) and a new Hoya Vivinex Multisert® XY1-SP IOL (29 patients, 31 eyes, group 2). IOL viscoimplantation was performed in 100 % of cases in group 1; in group 2 viscoimplantation was done in 45.1 % of cases and hydroimplantation in 54.9 %. Intraoperatively, corneal incision size was measured with a ruler before and after IOL implantation. Results In both groups, there was a statistically significant (p<0.05) increase of UCDVA from 0.28±0.09 in the preoperative period to 0.7±0.17 3 months after surgery in group 1 and from 0.24±0.10 in the preoperative period to 0.84±0.18 3 months after surgery in group 2. Slightly lower values of UCDVA in group 1 may be associated with a higher level of surgically induced astigmatism (SIA) in this group. Similar dynamics was shown for BCDVA (from 0.52±0.21 before surgery to 0.95±0.19 after 3 months of follow-up in group 1 and from 0.55±0.20 before surgery to 0.98±0.21 after 3 months of follow-up in group 2). No difference was found between the studied groups. After IOL implantation, there was an increase in incision size to 2.4±0.12 mm in group 1 and 2.1±0.08 mm in group 2 (p=0.04). Mean SIA after 3 months of observation was 1.1±0.16 D in group 1 and 0.48±0.07 D in group 2 (p=0.0007). Conclusion. This study presents a comparative analysis of implantation results with monofocal hydrophobic acrylic Hoya Vivinex IOL in a Multisert® preloaded injector and monofocal Hoya 250/251 IOLs in an Isert® injector. The advantage of the new IOL implantation in reducing the incidence of surgically induced astigmatism was shown.